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To the Editor
Data on safety and efficacy of ruxolitinib treatment in
myeloproliferative neoplasms (MPN) with concomitant
thrombocytopenia are scarce and limited to patients with
myelofibrosis (MF). It was demonstrated that 11–16% of
MF patients had platelet (PLT) count \50 9 109/l at
diagnosis and the rate of thrombocytopenia increases with
disease progression. Thrombocytopenia in MF may be due
to ineffective megakaryocytopoiesis as a result of bone
marrow fibrosis or results from platelet sequestration and
destruction in enlarged spleen [1]. Immune dysregulation
with the production of immune complexes or antiplatelet
antibodies may account for low platelet count in single
cases [2]. It is noteworthy that thrombocytopenia remains
an exceptional finding in polycythemia vera (PV).
Ruxolitinib is the first and only approved JAK inhibitor
for the treatment of intermediate- and high-risk MF as well
as for PV patients with inadequate response to or are
intolerant of hydroxyurea. It should be mentioned that
thrombocytopenia was identified as the dose-limiting tox-
icity for ruxolitinib in MF and was the most common cause
of dose modifications. Grade 3/4 thrombocytopenia was
rarely seen in PV patients receiving ruxolitinib [3].
There has been a limited experience with ruxolitinib in
thrombocytopenic patients with MPN, and all available
data were derived from studies in MF. Based on these
preliminary results, the treatment with low dose of
ruxolitinib (10 mg daily) was well tolerated and resulted in
spleen reduction with PLT count improvement. To date,
only few MF patients with PLT count of\50 9 109/l were
successfully treated with ruxolitinib [1, 4].
A 25-year-old female initiated a diagnostic workup due
to progressive thrombocytopenia. Seven years earlier, she
was diagnosed with polycythemia vera (PV) with
detectable H538–K539delinsL mutation in the exon 12 of
the JAK2 gene. Since her PV diagnosis she was phle-
botomized every other month and receiving hydroxyurea
and interferon with no effect. During the follow-up, she
developed an isolated mild thrombocytopenia (110 9 109/
l). She did not present a prior history of immune throm-
bocytopenia or any other autoimmune disorders.
On her current admission the white blood cell (WBC)
count was 28.1 9 109/l with the predominance of seg-
mented cells in differential (78%). No myeloid precursors
were found. Red blood cell (RBC) and PLT counts were
5.98 9 106/ll and 21 9 109/l, respectively. A massive
splenomegaly (40 cm) was found on ultrasonography. On
trephine biopsy her marrow cellularity was 100%. She had
reticullin fibrosis of grade I and megakaryocytes were
numerous with normal maturation. Blast cells were not
seen. Cytogenetics detected normal diploid karyotype. She
was found to have antiplatelet antibodies and received
steroids with no PLT increase. Then, she was started with
ruxolitinib at reduced dose of 15 mg daily due to grade 4
thrombocytopenia. A slow increase in PLT count was
observed with concomitant spleen reduction. Five months
later, her PLT count was 44 9 109/l, and ruxolitinib dose
was increased to 30 mg daily. At 15 months of ruxolitinib
treatment, her PLT count was 93 9 109/l with further
spleen reduction (17 cm on ultrasound). Figure 1. How-
ever, her RBC and WBC counts were elevated, and she
required regular phlebotomies. A repeated trephine biopsy
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remained unchanged, and the exon 12 mutation was still
present.
To date, coexistence of PV with immune thrombocy-
topenic purpura (ITP) was reported in three cases. All
patients were male[60 years old with the JAK2 V617F-
positive PV and PLT counts ranging from 8 to 29 9 109/l.
Of note is that they did not exhibit a significant spleno-
megaly on physical examination, and ITP diagnosis was
established by exclusion of other causes of thrombocy-
topenia. Moreover, low PLT count increased after steroids
introduction [2]. Our PV patient presented with severe
thrombocytopenia which was related to two independent
mechanisms (1) the presence of autoimmunity and (2)
hypersplenism. Of note is that steroids were ineffective.
The incorporation of ruxolitinib at 15 mg daily resulted in
slow platelet recovery without side effects. However no
improvements of PV features were observed despite time-
dependent dose increase and patient remains phlebotomy
dependent. It seems likely that the increase in PLT count
was most of all associated with reduction of spleen size. It
was found that patients with immune thrombocytopenia
have an increased Th17 population and defective function
of regulatory T cells (Tregs) [5]. The recent data show that
treatment with ruxolitinib resulted in a significant reduction
of regulatory Tregs and polarization of CD4? cells from a
Th1 to a Th17 phenotype [6]. In this context, ruxolitinib
treatment should rather deepen thrombocytopenia than
improve it. These data may prove against the beneficial
immunomodulatory effect of JAK inhibition in ITP.
To our best knowledge, this is the first report showing
the recovery of severe thrombocytopenia after ruxolitinib
for PV.
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Fig. 1 Graphical representation
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